rs281864524
Positions:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The ENST00000647020.1(HBB):c.-100G>A variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000024 in 833,510 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000022 ( 0 hom. )
Consequence
HBB
ENST00000647020.1 5_prime_UTR
ENST00000647020.1 5_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.0570
Genes affected
HBB (HGNC:4827): (hemoglobin subunit beta) The alpha (HBA) and beta (HBB) loci determine the structure of the 2 types of polypeptide chains in adult hemoglobin, Hb A. The normal adult hemoglobin tetramer consists of two alpha chains and two beta chains. Mutant beta globin causes sickle cell anemia. Absence of beta chain causes beta-zero-thalassemia. Reduced amounts of detectable beta globin causes beta-plus-thalassemia. The order of the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.54).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HBB | NM_000518.5 | upstream_gene_variant | ENST00000335295.4 | NP_000509.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HBB | ENST00000335295.4 | upstream_gene_variant | 1 | NM_000518.5 | ENSP00000333994 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152182Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
6
AN:
152182
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000220 AC: 15AN: 681210Hom.: 0 Cov.: 9 AF XY: 0.0000247 AC XY: 9AN XY: 363938
GnomAD4 exome
AF:
AC:
15
AN:
681210
Hom.:
Cov.:
9
AF XY:
AC XY:
9
AN XY:
363938
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152300Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74468
GnomAD4 genome
AF:
AC:
5
AN:
152300
Hom.:
Cov.:
33
AF XY:
AC XY:
2
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 15, 2023 | Variant summary: HBB c.-100G>A is located in the untranscribed region upstream of the HBB gene region. The variant allele was found at a frequency of 3.2e-05 in 31396 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance.c.-100G>A was initially reported in compound heterozygosity with pathogenic variant c.126_129delCTTT in a Chinese boy affected with Beta Thalassemia Major (Li_2009). However, a recent study reported the variant in eight simple heterozygotes with normal hematological parameters and it two compound heterozygous individuals (with known pathogenic variants c.126_129delCTTT and c.316-197C>T) with typical hematological parameters of b-thal trait. The authors of this study concluded that c.-100G>A is likely a silent beta-thal allele (Zhao_2020). Additionally, other recent studies reported detection of the variant in a large number of carrier Chinese individuals (e.g. He_2017, Zhang_2019, Peng_2021, Tan_2021). Of particular interest is the reporting of individuals with hematological parameters indicative of carrier status who were found to be homozygous for the variant of interest (n=1) or had other known pathogenic HBB variants (c.126_129delCTTT, c.217dupA) (e.g. He_2017, Zhang_2019). These data do not allow any conclusion about variant significance. Experimental evidence evaluating an impact on protein function demonstrated the variant results in mildly reduced mRNA levels and promoter activity (Li_2009, Kircher_2019). The following publications have been ascertained in the context of this evaluation (PMID: 28125089, 31395865, 19290524, 32986258, 25526804, 33439495, 25471338, 24055728, 30809867, 32674615, 36519257, 35119136). Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
beta Thalassemia Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
alpha Thalassemia;C0002895:Hb SS disease;C0019025:Hereditary persistence of fetal hemoglobin;C0700299:Heinz body anemia;C1840779:METHEMOGLOBINEMIA, BETA TYPE;C1858990:Dominant beta-thalassemia;C1970028:Malaria, susceptibility to;C4693822:Erythrocytosis, familial, 6;CN322236:Beta-thalassemia HBB/LCRB Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 20, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 24, 2023 | The HBB c.-100G>A variant has been reported in the published literature in an individual with beta-thalassemia major who was a compound heterozygote for this variant and the HBB c.126_129delCTTT (CDs 41–42 (-TTCT) variant (PMID: 19290524 (2009)). It has also been identified in carrier screens in the Chinese population (PMIDs: 33439495 (2021), 32986258 (2021), 30275481 (2019), 30809867 (2019), 28125089 (2017)). It has been described as a beta(+) variant. Functional studies suggest conflicting reports as to whether or not this variant impacts protein function (PMIDs: 31395865 (2019) and 19290524 (2009)). The frequency of this variant in the general population, 0.000032 (1/31396 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at